within Pharmacolibrary.Drugs.C_CardiovascularSystem.C07A_BetaBlockingAgents.C07AB03_Atenolol;
model Atenolol 
   extends Pharmacolibrary.Drugs.ATC.C.C07AB03;

  annotation(Documentation(
    info ="<html><body><p>Atenolol is a cardioselective beta-1 adrenergic blocker used primarily to treat hypertension, angina pectoris, and acute myocardial infarction. It is widely approved and utilized as an antihypertensive and antianginal agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Kirch, W, &amp; Görg, KG (1982). Clinical pharmacokinetics of atenolol--a review. <i>European journal of drug metabolism and pharmacokinetics</i> 7(2) 81–91. DOI:<a href=&quot;https://doi.org/10.1007/BF03188723&quot;>10.1007/BF03188723</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6749509/&quot;>https://pubmed.ncbi.nlm.nih.gov/6749509</a></p></li><li><p>McClellan, KJ, &amp; Markham, A (1998). Telmisartan. <i>Drugs</i> 56(6) 1039–1046. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199856060-00007&quot;>10.2165/00003495-199856060-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9878991/&quot;>https://pubmed.ncbi.nlm.nih.gov/9878991</a></p></li><li><p>Frost, C, et al., &amp; LaCreta, F (2017). The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. <i>Clinical pharmacology : advances and applications</i> 9 19–28. DOI:<a href=&quot;https://doi.org/10.2147/CPAA.S115687&quot;>10.2147/CPAA.S115687</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28260951/&quot;>https://pubmed.ncbi.nlm.nih.gov/28260951</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Atenolol;
